tetano
Editor, Senior Moderator
J Infect Dis. 2018 Apr 10. doi: 10.1093/infdis/jiy115. [Epub ahead of print]
[h=1]Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection.[/h] Wang Y[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Guo Q[SUP]4[/SUP], Yan Z[SUP]5[/SUP], Zhou D[SUP]6[/SUP], Zhang W[SUP]7[/SUP], Zhou S[SUP]8[/SUP], Li YP[SUP]9[/SUP], Yuan J[SUP]10[/SUP], Uyeki TM[SUP]11[/SUP], Shen X[SUP]12[/SUP], Wu W[SUP]13[/SUP], Zhao H[SUP]14[/SUP], Wu YF[SUP]15[/SUP], Shang J[SUP]16[/SUP], He Z[SUP]17[/SUP], Yang Y[SUP]18[/SUP], Zhao H[SUP]19[/SUP], Hong Y[SUP]20[/SUP], Zhang Z[SUP]21[/SUP], Wu M[SUP]22[/SUP], Wei T[SUP]23[/SUP], Deng X[SUP]24[/SUP], Deng Y[SUP]25[/SUP], Cai LH[SUP]26[/SUP], Lu W[SUP]27[/SUP], Shu H[SUP]28[/SUP], Zhang L[SUP]29[/SUP], Luo H[SUP]30[/SUP], Ing Zhou Y[SUP]31[/SUP], Weng H[SUP]32[/SUP], Song K[SUP]33[/SUP], Yao L[SUP]34[/SUP], Jiang M[SUP]35[/SUP], Zhao B[SUP]36[/SUP], Chi R[SUP]37[/SUP], Guo B[SUP]38[/SUP], Fu L[SUP]39[/SUP], Yu L[SUP]40[/SUP], Min H[SUP]41[/SUP], Chen P[SUP]42[/SUP], Chen S[SUP]43[/SUP], Hong L[SUP]44[/SUP], Mao W[SUP]45[/SUP], Huang X[SUP]46[/SUP], Gu L[SUP]47[/SUP], Li H[SUP]2,[/SUP][SUP]3[/SUP], Wang C[SUP]2,[/SUP][SUP]3,[/SUP][SUP]48[/SUP], Cao B[SUP]2,[/SUP][SUP]3[/SUP]; CAP-China Network.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Background:[/h] Data are limited on the impact of neuraminidase inhibitor (NAI) treatment on avian influenza A(H7N9) virus RNA shedding.
[h=4]Methods:[/h] In this multicenter, retrospective study, data were collected from adults hospitalized with A(H7N9) infection during 2013-2017 in China. We compared clinical features and A(H7N9) shedding among patients with different NAI doses and combination therapies and evaluated factors associated with A(H7N9) shedding, using Cox proportional hazards regression.
[h=4]Results:[/h] Among 478 patients, the median age was 56 years, 71% were male, and 37% died. The median time from illness onset to NAI treatment initiation was 8 days (interquartile range [IQR], 6-10 days), and the median duration of A(H7N9) RNA detection from onset was 15.5 days (IQR, 12-20 days). A(H7N9) RNA shedding was shorter in survivors than in patients who died (P < .001). Corticosteroid administration (hazard ratio
, 0.62 [95% confidence interval {CI}, .50-.77]) and delayed NAI treatment (HR, 0.90 [95% CI, .91-.96]) were independent risk factors for prolonged A(H7N9) shedding. There was no significant difference in A(H7N9) shedding duration between NAI combination treatment and monotherapy (P = .65) or between standard-dose and double-dose oseltamivir treatment (P = .70).
[h=4]Conclusions:[/h] Corticosteroid therapy and delayed NAI treatment were associated with prolonged A(H7N9) RNA shedding. NAI combination therapy and double-dose oseltamivir treatment were not associated with a reduced A(H7N9) shedding duration as compared to standard-dose oseltamivir.
PMID: 29648602 DOI: 10.1093/infdis/jiy115
[h=1]Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection.[/h] Wang Y[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Guo Q[SUP]4[/SUP], Yan Z[SUP]5[/SUP], Zhou D[SUP]6[/SUP], Zhang W[SUP]7[/SUP], Zhou S[SUP]8[/SUP], Li YP[SUP]9[/SUP], Yuan J[SUP]10[/SUP], Uyeki TM[SUP]11[/SUP], Shen X[SUP]12[/SUP], Wu W[SUP]13[/SUP], Zhao H[SUP]14[/SUP], Wu YF[SUP]15[/SUP], Shang J[SUP]16[/SUP], He Z[SUP]17[/SUP], Yang Y[SUP]18[/SUP], Zhao H[SUP]19[/SUP], Hong Y[SUP]20[/SUP], Zhang Z[SUP]21[/SUP], Wu M[SUP]22[/SUP], Wei T[SUP]23[/SUP], Deng X[SUP]24[/SUP], Deng Y[SUP]25[/SUP], Cai LH[SUP]26[/SUP], Lu W[SUP]27[/SUP], Shu H[SUP]28[/SUP], Zhang L[SUP]29[/SUP], Luo H[SUP]30[/SUP], Ing Zhou Y[SUP]31[/SUP], Weng H[SUP]32[/SUP], Song K[SUP]33[/SUP], Yao L[SUP]34[/SUP], Jiang M[SUP]35[/SUP], Zhao B[SUP]36[/SUP], Chi R[SUP]37[/SUP], Guo B[SUP]38[/SUP], Fu L[SUP]39[/SUP], Yu L[SUP]40[/SUP], Min H[SUP]41[/SUP], Chen P[SUP]42[/SUP], Chen S[SUP]43[/SUP], Hong L[SUP]44[/SUP], Mao W[SUP]45[/SUP], Huang X[SUP]46[/SUP], Gu L[SUP]47[/SUP], Li H[SUP]2,[/SUP][SUP]3[/SUP], Wang C[SUP]2,[/SUP][SUP]3,[/SUP][SUP]48[/SUP], Cao B[SUP]2,[/SUP][SUP]3[/SUP]; CAP-China Network.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Background:[/h] Data are limited on the impact of neuraminidase inhibitor (NAI) treatment on avian influenza A(H7N9) virus RNA shedding.
[h=4]Methods:[/h] In this multicenter, retrospective study, data were collected from adults hospitalized with A(H7N9) infection during 2013-2017 in China. We compared clinical features and A(H7N9) shedding among patients with different NAI doses and combination therapies and evaluated factors associated with A(H7N9) shedding, using Cox proportional hazards regression.
[h=4]Results:[/h] Among 478 patients, the median age was 56 years, 71% were male, and 37% died. The median time from illness onset to NAI treatment initiation was 8 days (interquartile range [IQR], 6-10 days), and the median duration of A(H7N9) RNA detection from onset was 15.5 days (IQR, 12-20 days). A(H7N9) RNA shedding was shorter in survivors than in patients who died (P < .001). Corticosteroid administration (hazard ratio
, 0.62 [95% confidence interval {CI}, .50-.77]) and delayed NAI treatment (HR, 0.90 [95% CI, .91-.96]) were independent risk factors for prolonged A(H7N9) shedding. There was no significant difference in A(H7N9) shedding duration between NAI combination treatment and monotherapy (P = .65) or between standard-dose and double-dose oseltamivir treatment (P = .70).
[h=4]Conclusions:[/h] Corticosteroid therapy and delayed NAI treatment were associated with prolonged A(H7N9) RNA shedding. NAI combination therapy and double-dose oseltamivir treatment were not associated with a reduced A(H7N9) shedding duration as compared to standard-dose oseltamivir.
PMID: 29648602 DOI: 10.1093/infdis/jiy115